reviewTop 10% cited
Rituximab
Drugs · 2003 · Vol. 63(8) · pp. 803–843
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentLung Cancer Research StudiesMedicineRituximabVincristineCHOPInternal medicinePrednisoneAdverse effectLymphomaCyclophosphamideChemotherapy
MeSH terms
RituximabAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicDrug Administration ScheduleHumansLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellAntibodies, Monoclonal, Murine-Derived
Citations
470
FWCI
9.92
field-weighted impact
References
114
Percentile
99%
vs. same field & year
Citations per year
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Cells · 2020 · 887 citations
Microtubules as a target for anticancer drugs
Nature reviews. Cancer · 2004 · 4,414 citations
References
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Blood · 1994 · 1,936 citations
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
Blood · 1996 · 1,819 citations
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Blood · 1997 · 1,692 citations
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Journal of Clinical Oncology · 1999 · 3,489 citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Journal of Clinical Oncology · 1998 · 2,755 citations
Cancer Statistics, 2001
CA A Cancer Journal for Clinicians · 2001 · 3,319 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.